Viking Therapeutics Files 10-K Report, Highlighting R&D Focus and Phase 3 Plans

Viking Therapeutics (VKTX) has filed its annual 10-K report with the SEC, detailing its financial position as a clinical-stage biotechnology firm. The company reported zero revenue for the fiscal year, reflecting its current focus on the development of its primary drug candidates, VK2735 and VK2809. Significant capital has been allocated toward research and development (R&D) to advance these treatments for obesity and NASH. Looking ahead, the company outlined strategic plans for upcoming Phase 3 clinical trials and robust capital management strategies. Investors remain focused on these clinical milestones as the primary drivers for future growth. The report underscores the high-risk, high-reward nature of the biotech sector during the pre-commercialization phase.